CDKN2A and cancer: In addition to the recommendation for genetic counseling, three variants likely associated with an autosomal dominant cancer disposition supported a treatment recommendation, twice for PARP inhibition (BRCA1, CHEK2) and once for CDK4/6 inhibition (CDKN2A).